This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Verona Pharma PLC American Depositary Share (VRNA) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
Verona Pharma PLC American Depositary Share (VRNA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Best Momentum Stocks to Buy for July 20th
by Zacks Equity Research
AN, LAD, and VRNA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 20, 2022.
How Much Upside is Left in Verona Pharma PLC American Depositary Share (VRNA)? Wall Street Analysts Think 283%
by Zacks Equity Research
The consensus price target hints at a 283.3% upside potential for Verona Pharma PLC American Depositary Share (VRNA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Best Momentum Stocks to Buy for July 14th
by Zacks Equity Research
LW, VRNA and JBI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 14, 2022.
New Strong Buy Stocks for July 14th
by Zacks Equity Research
CHMG, CQP, VRNA, JBI and SYY have been added to the Zacks Rank #1 (Strong Buy) List on July 14, 2022.
Company News for Jun 11, 2021
by Zacks Equity Research
Companies in the news are: SIG, XIN, VRNA, PFE
Verona (VRNA) Initiates Pivotal COPD Studies on Ensifentrine
by Zacks Equity Research
Verona Pharma (VRNA) is developing twice-daily nebulized formulation of ensifentrine as potential maintenance treatment for COPD.
Has Verona Pharma PLC American Depositary Share (VRNA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (VRNA) Outperforming Other Medical Stocks This Year?
Top Ranked Momentum Stocks to Buy for August 6th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, August 6th.
Top Ranked Momentum Stocks to Buy for August 4th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 4th.
Top Ranked Momentum Stocks to Buy for July 31st
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, July 31st.
Top Ranked Momentum Stocks to Buy for July 29th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, July 29th.
Top Ranked Momentum Stocks to Buy for July 28th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, July 28th
Will Verona Pharma Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor of Verona Pharma
Will Verona Pharma Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Verona Pharma
Abeona Treats First Patient in Pivotal Gene Therapy Study
by Zacks Equity Research
Abeona (ABEO) treats first patient in a pivotal study evaluating its gene-corrected cell therapy, EB-101, as a treatment for recessive dystrophic epidermolysis bullosa, a rare connective tissue disorder.
Verona Pharma Works Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Verona Pharma plc (VRNA) has been struggling lately, but the selling pressure may be coming to an end soon.
Verona Pharma Enters Oversold Territory
by Zacks Equity Research
Verona Pharma PLC American Depositary Share (VRNA) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Verona Pharma Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Verona Pharma has been struggling lately, but the selling pressure may be coming to an end soon.
The Zacks Analyst Blog Highlights: Verona, Squibb, Protagonist and Amgen
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Verona, Squibb, Protagonist and Amgen
Zacks Investment Ideas feature highlights: Floor & Decor Holdings, Verona Pharma, Emerald Expositions Events, Carvana and Couldera
by Zacks Equity Research
Zacks Investment Ideas feature highlights: Floor & Decor Holdings, Verona Pharma, Emerald Expositions Events, Carvana and Couldera